Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis

Wei Ma, Lei Guo, Ling Shan, Xiuyun Liu, Ning Lyu & Jianming Ying

Translocation of anaplastic lymphoma kinase (ALK) gene is an important determinator for the response to ALK tyrosine kinase inhibitor (TKI) in non-small-cell lung cancer (NSCLC) patients. The existence of genetic heterogeneity will affect the results of molecular testing, especially in biopsy samples from primary or metastatic sites of patients with advanced stage NSCLC. We intended to explore the heterogeneity of ALK gene translocation in excision specimens and to examine the existence of discordance of ALK status between primary tumours and corresponding lymph node metastases. A total of 106 ALK positive lung adenocarcinoma cases were collected for assessment of intratumour heterogeneity of ALK gene translocation, which were stained by the fully automated Ventana ALK D5F3 immunohistochemistry (IHC) analysis. In addition, the ALK gene translocations were evaluated in a series of 53 primary tumours and their paired lymph node metastases using ALK D5F3 IHC staining. The concordance rate between primary tumours and paired metastatic lymph nodes was 100%. ALK status was homogeneous in lung adenocarcinoma samples and was generally stable during metastasis. Therefore, ALK gene translocation can be measured reliably in material from either primary or metastatic tumours in lung adenocarcinoma patients.

Lung cancer causes the largest number of cancer related deaths worldwide. Currently, more than 85% of lung cancer cases are classified as non-small-cell-lung cancer (NSCLC). Adenocarcinoma is the most common histological type of NSCLC1. Although conventional chemotherapy is the main treatment for the majority of advanced NSCLC patients, new targeted therapies have been developed for a subset of patients harboring key oncogenic alterations2. For example, drugs targeting epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations have been successfully used in clinical medicine2, 3. ALK gene translocation was first discovered in NSCLC in 20074. This translocation results from a small inversion in chromosome 2p leading to aberrant ALK gene translocation expression in the cytoplasm and uncontrolled cellular proliferation and survival4, 5. The US Food and Drug Administration (FDA) have approved crizotinib and ceritinib, the first and second-generation ALK inhibitors respectively6. The identification of ALK gene translocation in NSCLC is the basis of targeted therapy with ALK inhibitors. Three methods have been utilized to detect ALK gene translocations: fluorescent in situ hybridisation (FISH), real-time reverse transcription-PCR (RT-PCR), and novel fully automated Ventana ALK D5F3 immunohistochemistry (IHC). Previous study by Ying et al. has demonstrated the 100% sensitivity and 98% specificity of the Ventana ALK assay, respectively7.

The morphology and genetics of tumour heterogeneity are topics of great interest in cancer research8. Recently, several solid malignant tumours have been found to be genetically heterogeneous8–10. For example, IHC analysis showed that EGFR expression in primary NSCLC tumour/metastasis had a discordance rate of 33.3%10. In this study, we applied Ventana ALK D5F3 IHC to investigate the heterogeneity of ALK gene translocations in excision specimens and compared the ALK status between primary tumours and their corresponding metastatic lymph nodes.

ALK gene translocation was previously found to be mutually exclusive with other driver gene mutations11. However, several recent reports have identified an overlap between ALK translocation and other driver gene

Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Correspondence and requests for materials should be addressed to N.L. (email: nlu03@126.com) or J.Y. (email: jmying@cicams.ac.cn)
mutations\(^\text{12-17}\). Here, we analyze the association of ALK gene translocation with the occurrence of other driver gene mutations by directly sequencing the \(\text{EGFR}\), \(\text{KRAS}\), \(\text{BRAF}\), and \(\text{HER2}\) gene mutations and with clinicopathological characteristics.

## Results

### Characteristics of ALK-positive lung adenocarcinoma samples

Clinicopathological features of 106 ALK-immunopositive cases were compared with 90 ALK-immunonegative cases (Table 1). The median age of patients with ALK-positive was 52.5 years (28–77 years) among 51 men and 55 women. At the time of resection, 45 (42.5%), 10 (9.4%) and 51 (48.1%) patients with ALK-positive were in Stages I, II and III, respectively. Among these cases, 54.7% (58/106) had lymph node metastasis. ALK-positive cases occurred in younger patients (\(p=0.020\)), and they presented at a higher clinical stage (\(p<0.001\)). Compared with ALK-negative patients, ALK-positive tumours were more likely to show lymph node metastases (\(p<0.001\)). There was no significant difference in smoking history and family history of cancer among these two groups of patients (\(p>0.05\)).

### Histological characteristics of ALK-positive lung adenocarcinoma samples

The histological characteristics of ALK-positive tumours are illustrated in Table 2. Although ALK-positive cases were not significantly associated with acinar predominant growth pattern (\(p=0.373\)), they were positively associated with micropapillary (\(p<0.001\)) and solid predominant growth pattern (\(p=0.005\)).

### ALK gene translocation status in primary tumour cells

All 106 ALK-positive cases were successfully examined by ALK D5F3 IHC. All cases showed diffused cytoplasmic staining pattern in the section of FFPE tissue tumour samples, without diverse signal intensities (Fig. 1B). All ALK-positive cases in this study showed a homogeneous strong ALK-expression of all neoplastic cells.

### ALK gene translocation status in the lymph node metastases

Fifty three patients (53/196, 27%), including 37 ALK-positive cases and 16 ALK-negative cases, with paired primary tumours and lymph node metastases samples were further investigated for concordance of ALK status. Among these 53 paired sample patients, pathological N1 disease was confirmed in 10 (18.9%) patients, N2 disease in 42 (79.2%) patients and

---

| characteristics | ALK-positive | ALK-negative | \(P\) |
|----------------|-------------|-------------|-----|
| Age, years     |             |             |     |
| Median (range) | 52.5 (28–77) | 61.0 (41–76) |     |
| <65            | 88 (83.0)   | 62 (68.9)   | 0.020 |
| \(\geq65\)     | 18 (17.0)   | 28 (31.1)   | 0.721 |
| Sex            |             |             |     |
| Male           | 51 (48.1)   | 41 (45.6)   |     |
| Female         | 55 (51.9)   | 49 (54.4)   | 0.689 |
| Family history of cancer | | | |
| Yes            | 31 (29.2)   | 24 (26.7)   |     |
| No             | 75 (70.8)   | 66 (73.3)   | 0.833 |
| Smoking history|             |             |     |
| Never          | 71 (67.0)   | 59 (65.6)   |     |
| Formal and current | 35 (33.0) | 31 (34.4) |     |
| Tumor status   |             |             |     |
| T1             | 34 (32.1)   | 27 (30.0)   |     |
| T2             | 58 (54.7)   | 52 (57.8)   |     |
| T3             | 10 (9.4)    | 6 (6.7)     |     |
| T4             | 4 (3.8)     | 5 (5.6)     |     |
| Lymph node status |         |             |     |
| N0             | 48 (45.3)   | 71 (78.9)   |     |
| N1             | 9 (8.5)     | 7 (7.8)     |     |
| N2             | 48 (45.3)   | 11 (12.2)   |     |
| N3             | 1 (0.9)     | 1 (1.1)     |     |
| Stage          |             |             |     |
| I              | 45 (42.5)   | 61 (67.8)   |     |
| II             | 10 (9.4)    | 13 (14.4)   |     |
| III            | 51 (48.1)   | 35 (16.7)   |     |
| IV             | 0 (0.0)     | 1 (1.1)     |     |

Table 1. Clinicopathologic Characteristics of ALK-positive and ALK-negative Lung adenocarcinoma samples. \(^*\)T1 and T2 versus T3 and T4. \(^*\)N0 versus N1 and 2 and 3. \(^*\)Stage I and II versus stage III and IV.
N3 disease in 1 (1.9%) patient. The characteristics of these 53 paired cases are illustrated in Table 3. Lymph node metastases from the 37 \( \text{ALK}^+ \) cases were examined and \( \text{ALK}^+ \) expression with diffused cytoplasmic staining pattern exhibited in all lymph node metastases (Fig. 1D). \( \text{ALK}^+ \) expression was absent in the metastases of the 16 patients with no \( \text{ALK} \) expression in their primary tumours. No discordant case of \( \text{ALK} \) expression was observed between the primary tumours and their corresponding lymph node metastases (Table 4).

### Table 2. Histologic characteristics of ALK-positive lung adenocarcinoma samples. Abbreviation: IMA, invasive mucinous adenocarcinoma.

| Histologic subtype | \( \text{ALK}^+ \) N = 106(%) | \( \text{ALK}^- \) N = 90(%) | \( p \) |
|--------------------|----------------|----------------|------|
| Lepidic            | 5 (4.7) | 7 (7.8) | 0.373 |
| Acinar             | 2 (1.9) | 2 (2.2) | 0.869 |
| Papillary          | 13 (12.3) | 15 (16.7) | 0.380 |
| Micropapillary     | 25 (23.6) | 4 (4.4) | <0.001 |
| Solid              | 9 (8.5) | 0 (0.0) | 0.005 |
| IMA                | 52 (49.1) | 62 (68.9) | 0.005 |

Figure 1. \( \text{ALK} \) gene status determined by the Ventana D5F3 IHC in primary tumour and corresponding lymph node metastasis. A representative case is shown: graph of the primary tumour under light microscopy (hematoxylin and eosin, \( \times \) 200) (A) and strong immunoreactivity of \( \text{ALK}-\text{D5F3} \) in the primary tumour (B) (\( \times \)200); Graph of the corresponding lymph node metastasis under light microscopy (hematoxylin and eosin, \( \times \)200) on TMA (C) and strong immunoreactivity of \( \text{ALK}-\text{D5F3} \) in the corresponding lymph node metastasis (D) (\( \times \)200).

Analysis of \( \text{EGFR} \), \( \text{KRAS} \), \( \text{BRAF} \) and \( \text{HER2} \) genetic alterations in 106 \( \text{ALK}^+ \) cases. Genotyping for \( \text{EGFR} \), \( \text{KRAS} \), \( \text{BRAF} \) and \( \text{HER2} \) mutations was conducted with direct sequencing in the \( \text{ALK}^+ \) cases. \( \text{EGFR} \) mutations were detected in 5 (4.7%) cases. However, \( \text{KRAS} \), \( \text{BRAF} \) and \( \text{HER2} \) mutations were not detected in any specimens. \( \text{EGFR} \) mutation types and locations are shown in Table 5. Three cases with deletions in exon 19, whereas two had mutations in exon 21 (L858R).
Discussion

Tumour heterogeneity refers to the existence of subpopulations of cells with distinct genotypes and phenotypes that may harbour divergent biological behaviors, within a primary tumour and its metastases; alternatively the divergence is between tumours of the same histopathological subtype, even between spatially separated regions within single biopsies (intra- and inter-tumour, respectively). Investigation of tumour heterogeneity will provide valuable information for diagnostic and/or therapeutic procedures.

The selection of patients for crizotinib therapy relies on the ALK status of the tumour. Thus, accurate determination of ALK status is crucial to ensure the potential clinical benefit of ALK inhibitors and to avoid the toxic effects in inappropriately selected patients. The most commonly treatment-related adverse reactions in crizotinib therapy were vision disorder, gastrointestinal disorders and oedema. Majority of the ALK gene translocation status are evaluated in primary tumours of NSCLC and in practice, most clinical decision-making for patients with advanced NSCLC depends on single-tumour biopsy samples from primary or metastatic sites, even from cytological specimens. Therefore, the biomarker status is assumed to remain unchanged during metastatic progression.
In the present study, we evaluated the intratumour heterogeneity of ALK gene translocation in 106 ALK-positive excision specimens by the Ventana ALK D5F3 IHC and also investigated whether the ALK status changed during disease progression in 53 pairs of primary tumours and corresponding lymph node metastases. We found the ALK expression was homogenous in lung adenocarcinoma samples and there was no discordant case of ALK status between primary tumours and corresponding lymph node metastases. Therefore, primary tumours can clearly represent the ALK status of the metastatic tumours. The ALK status remained unchanged during metastasis.

Metastatic advanced lung cancer continues to represent a major health problem worldwide. Targeted therapies are the standard therapeutic options for these patients. Approximately 70–85% of new lung cancers are unsuitable for surgical therapy; thus, only small biopsy specimens are available for diagnosis or further genetic detection. By examining the ALK status in the primary tumours and corresponding metastatic tumours in our series, we propose that ALK gene translocation is a stable genetic alteration once it has occurred. This hypothesis has important clinical implications. Firstly, fine needle biopsy or aspiration of primary and/or metastatic tumours and pleural effusions are feasible for the detection of ALK gene translocations. Secondly, despite the marked antitumour activity of crizotinib, some ALK-positive patients developed resistant to crizotinib on average within the first year or two of TKI therapy. In general, crizotinib resistance in ALK-positive NSCLC occurs through secondary resistance mutations located in the ALK TK domain, amplification of the ALK fusion gene, and activation of bypass tracks. Therefore, we suggested that a change in ALK status between the primary tumour and metastasis was not the cause of crizotinib resistance.

Previous studies have demonstrated the intratumour heterogeneity of ALK gene translocation in lung adenocarcinoma samples. Cai et al. acquired 45 spatially separated tumour cell subpopulations using laser-capture microdissection from 20 patients with ALK-FISH positivity. A total of 33 lesions were positive for ALK translocation by RT-PCR and 34 lesions were positive for ALK translocation, but 11 lesions were ALK wild-type regions. Abe et al. observed a total of 64 tumour areas in nine ALK-FISH positive cases using darkfield fluorescence microscopy; positive ALK was found in 50 areas. However, in the current study with the Ventana ALK-DSF3 IHC, we did not detect intratumour heterogeneity of ALK status because ALK protein expression was diffusely positive in all neoplastic cells. Several studies considered that the intratumoural ALK gene translocation heterogeneity may be associated with technical problems. Camidge et al. recorded the percentage of positive cells, pattern of positivity (split, single red, or both), and copy number of fused, isolated red and green signals by evaluating 90 ALK FISH positive NSCLC cases. They concluded that the semivertical orientation of tumour cells and/or nuclear truncation in paraffin-embedded tissue sections may make precise identification of break-apart signals difficult. Proietti et al. reported that FISH on conventional cytology, in which tumour cells are arranged in a single layer, have much higher positive rates for FISH than histology specimens. Moreover, ALK FISH using small biopsy sections cannot examine as many fields and cells as is the case with excision samples. RT-PCR, proposed as an alternative screening method for ALK gene translocation, is also not recommended for the detection of ALK translocation. RT-PCR cannot be able to detect all fusion transcript variants. Additionally, RT-PCR is more stringent requirements for the sample preparation due to the rapid degradation of RNA.

The Ventana ALK D5F3 IHC detection system, measuring the expression of the ALK protein containing the C-terminal active kinase domain, is a sensitive method for detecting ALK gene translocation, especially in paraffin-embedded tissues, which was approved as a CE-IVD (in vitro diagnostic products) in Europe, China, and US since 2012, 2013 and 2015, respectively. We described a case with a negative FISH result that was later identified as ALK-positive by Ventana IHC and responded well to crizotinib. Targeted next generation sequencing revealed a new ALK partner gene (BIRC6) and the paracentric inversion for generating this fusion gene. Wekken A. et al. evaluated tumour response rate and survival after crizotinib treatment of 29 consecutive patients with ALK-advanced NSCLC diagnosed by FISH and/or Ventana ALK D5F3 IHC on small biopsies or fine needle aspirations (FNA). They concluded that ALK D5F3 IHC was superior to ALK-FISH on small biopsies and FNA to predict tumour response and survival to crizotinib for advanced NSCLC patients. Therefore, the Ventana IHC assay may be more sensitive than FISH for detecting ALK status in metastases and/or small biopsies which often contain only few tumour cells.

In this study, we found that a portion of lung adenocarcinoma patients with concomitant EGFR and ALK alterations. The dual-positive cases accounted for 4.7% (5/106) of ALK-positive lung adenocarcinoma samples using direct sequencing, which was similar to the ratio of 4.4% (4/91) reported by Won et al. but lower than the ratio of 18.6% (12/70) reported by Yang et al. both studies used the same detection method. Won et al. reported that the frequency of co-alteration detection increase in the same cohort when sensitive detection methods for EGFR mutation are applied, such as real-time PCR, targeted NGS, and mutant-enriched NGS. We reviewed the literatures and summarized the relevant clinicopathological and molecular characteristics of ALK/EGFR dual-positive cases; majority of cases were adenocarcinomas in the advanced stage and mainly involved Asian patients, most EGFR mutations were deletions in exon 19 and point mutations in exon 21, and patients showed differential sensitivities to EGFR-TKI and/or ALK-TKI.

Intratumour heterogeneity (ITH) has recently been elucidated in several cancer types with the use of next-generation sequencing (NGS) approaches. Clonal analyses by de Bruin et al. and Zhang et al. reported substantial intratumour heterogeneity (ITH) within lung adenocarcinoma samples, by using multiregion whole-exome sequencing (WES) and/or whole genome sequencing (WGS). Recent evidence supports a model of trunk-branched clonal evolution leading to variable ITH and complex clonal architecture of tumours. The clonal structure of a tumour is visually represented as a phylogenetic tree, the ubiquitous alterations present in all tumour regions map to the trunk, whereas heterogeneous events present in only some regions of the tumour map to the branches. The findings of homogeneous ALK gene translocation in lung adenocarcinoma samples, and concordant ALK status between primary and lymph node metastasis in this study, suggested that ALK gene translocation is a ubiquitous event, must occur very early in lung adenocarcinoma pathogenesis.
finding of ALK/EGFR coaltered lung adenocarcinoma cases may be explained by clonal evolutionary dynamics and the resulting complex clonal architecture of lung adenocarcinoma samples. In addition, in this study, we also demonstrated that ALK-positive cases more commonly showed lymph node metastasis and presented at higher clinical stage and ALK gene translocations were significantly more common in lung adenocarcinoma samples with micropapillary and solid predominant patterns which associated with poorer prognosis. We confirmed that tumour cells with ALK gene translocations contained enhanced metastatic potential and acquired the metastatic phenotype.

Conclusion
In summary, using the Ventana (D5F3) IHC, we found the homogeneity of ALK expression in lung adenocarcinoma samples and concordance in ALK status between primary tumours and corresponding lymph node metastases. Molecular testing for ALK translocation may be performed in either primary tumour or lymph node metastasis samples from the same patient. However, the main limitation in our study is that the metastases did not include different metastatic sites, especially distant metastases. Loco-regional or concurrent regional lymph node metastases are not considered to be biologically equivalent to distant metastases. We also found a small portion of lung adenocarcinoma samples have concomitant EGFR and ALK alterations by using direct sequencing. The clinical relevance of these concurrent alterations remains to be elucidated in future studies.

Methods
Patients and tumour samples. All formalin-fixed and paraffin-embedded (FFPE) tissue sections were obtained from patients with histologically confirmed primary lung adenocarcinoma. The patients previously underwent curative surgery at the Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, between February 2013 and February 2015. Written informed contents were obtained from all subjects before collecting the samples. All the methods were carried out in accordance with the institutional guidelines and approved by the Ethical Review Committee of the Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. Tumours were immunoassayed with ALK D5F3 antibody as described below. A total of 106 ALK-immunopositive cases were collected. Ninety ALK-immunonegative lung adenocarcinoma cases were randomly selected and included in the study as controls. The ALK status between primary tumours and their metastases was compared in 37 ALK-immunopositive and 16 ALK-immunonegative cases, as well as their corresponding metastatic lymph nodes. Thirty-seven ALK-positive cases with their corresponding metastatic lymph nodes were selected among 106 ALK-positive cases, meanwhile, 16 ALK-negative cases with their corresponding metastatic lymph nodes were selected among 90 ALK-negative cases. Our study included only metastatic tumour tissues with diameters greater than 0.5 cm from lymph nodes. The lymph node metastases of 53 cases were conducted into three tissue microarrays (TMA). Lymph node metastases were sampled by collecting 2.0 mm-diameter cores from two different representative sites based on hematoxylin and eosin (HE) stained sections.

Age, gender, cancer stage, smoking status and treatment of all patients were recorded. All cases had one slide stained for hematoxylin and eosin to confirm the presence of adequate tumour tissue. For each case, multiple slides corresponding to whole tissue sections were reviewed by two pathologists according to the 2011 International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) International Multidisciplinary Classification of Lung Adenocarcinoma and the American Joint Committee on Cancer (7th edition) of tumour, node and metastasis staging criteria. In mixed-subtype adenocarcinoma samples, we assessed the percentage of each histological pattern (Lepidic, Acinar, Papillary, Micropapillary, Solid) in 5% increments and recorded the predominant histological pattern. Cases with differences between the two reviewers were reevaluated and a consensus interpretation was rendered. None of patients had received prior ALK or EGFR TKI therapy.

Ventana IHC staining and scoring. ALK-IHC was performed on 4 μm-thick formalin fixed, paraffin-embedded tissue sections or TMA slides using the Ventana ALK D5F3 Dx assay on a Ventana Benchmark XT automated slide-processing system (Ventana Medical Systems Inc., Tucson, AZ). Briefly, slides of lung adenocarcinoma tumours were subjected to deparaffinization using EZ Prep (Ventana Medical Systems Inc.). Tissue sections were incubated with anti-ALK antibody (clone D5F3, Ventana Medical Systems Inc.) for 20 min. Optiview DAB IHC detection kit (Ventana Medical Systems Inc.) and Optiview amplification kit (Ventana Medical Systems Inc.) were used according to the manufacturer's recommendations for the visualization of the bound primary antibody. Tissue slides were counterstained with hematoxylin II and Bluing Reagent (Ventana Medical Systems Inc.). An ALK-positive cell lines embedded in agar/FFPE or sections of normal appendix containing ALK-positive ganglion cells, were used as ALK-IHC external controls in each run (Ventana Medical Systems Inc.). Two consecutive 4μm-thick FFPE tissue slices was cut, one slide was used in ALK-D5F3 IHC analysis, and the other for routine negative control staining for a matched rabbit monoclonal negative antibody (Ventana Medical Systems Inc.). For evaluating the staining results, a binary scoring system (positive or negative for ALK status) was used (package insert for VENTANA anti-ALK D5F3 Rabbit Monoclonal Primary Antibody, Cat.N0.790-4794/066790702001). Tumour cells with strong granular cytoplasmic staining (any percentage of positive tumour cells) were designated as ALK-positive, whereas tumour cells without strong granular cytoplasmic staining were designated as ALK-negative. Negative quality control sections were first evaluated for lack of staining. Considering that Ventana ALK D5F3 IHC produced more intense cytoplasmic signals because of excessive chromogen deposition, which resulted in false-positive staining, the ALK expression in our study was assessed independently by one trained scientist (J.Y.) and one pathologist (N.L.).
Direct sequencing of EGFR, KRAS, BRAF and HER2. Direct Sanger sequencing for EGFR, KRAS, BRAF and HER2 was conducted. Briefly, genomic DNA was extracted from 106 ALK-positive FFPE tissues. Mutations in exons 18–21 of EGFR, V600E of BRAF, exon 2 of KRAS, and exon 20 of HER2 were amplified by PCR. PCR products were then purified with QIAquick PCR purification kits (Qiagen, Hilden, Germany) and submitted for sequencing with an ABI 3500XL analyzer (Applied Biosystems, Carlsbad, CA, USA) with the POP7 polymer according to the manufacturer’s protocol. Details of the methodology were described in a previous study.

Statistical analysis. Fisher’s exact test was used to compare categorical data for clinicopathological characteristics between ALK-immunopositive and ALK-immunonegative subgroups. All p values are based on two-sided hypothesis test. The statistical analysis were conducted using SPSS version 17.0 software (SPSS, Chicago, IL, USA), and statistical significance was set as p < 0.05.

References
1. Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87–108, doi:10.3322/caac.21262 (2015).
2. Sholl, L. M. et al. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 768–777, doi:10.1097/JTO.0000000000000316 (2015).
3. Sasaki, T., Rodig, S. J., Chirieac, L. R. & Janne, P. A. The biology and treatment of EML4-ALK non-small cell lung cancer. European journal of cancer 46, 1773–1780, doi:10.1016/j.ejca.2010.04.002 (2010).
4. Soda, M. et al. Identification of the transforming E45-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566, doi:10.1038/nature05945 (2007).
5. Palmer, R. H., Vernersson, E., Grabbe, C. & Hallberg, B. Anaplastic lymphoma kinase: signalling in development and disease. The Biochemical journal 420, 345–361, doi:10.1042/BJ20093857 (2009).
6. Shaw, A. T. & Engelman, J. A. ALK in lung cancer: past, present, and future. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31, 1105–1111, doi:10.1200/JCO.2012.44.5535 (2013).
7. Ying, J. et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 24, 2588–2593, doi:10.1093/annonc/mdt285 (2013).
8. Fisher, R., Psutka, L. & Swanton, C. Anaplastic lymphoma kinase gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non-small cell lung cancer. Cancer 118, 4846–4849, doi:10.1002/cncr.27411 (2012).
9. Fisher, R. P. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72, 479–485, doi:10.1083/jbc.2012.581 (2013).
10. Gancberg, D. et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 17, 981–985, doi:10.1093/annonc/md038 (2006).
11. Gainor, J. F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 19, 4273–4281, doi:10.1158/1078-0432.CCR-13-0318 (2013).
12. Tuononen, K. et al. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients. Genes, chromosomes & cancer 53, 895–901, doi:10.1002/gcc.21998 (2014).
13. Won, J. K. et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 26, 348–354, doi:10.1093/annonc/mdu330 (2015).
14. Baldi, L. et al. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung cancer 86, 291–295, doi:10.1016/j.lungcan.2014.09.011 (2014).
15. Lee, J. K. et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung cancer 77, 460–463, doi:10.1016/j.lungcan.2012.04.012 (2013).
16. Chiari, R. et al. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32, e30–e32, doi:10.1200/JCO.2012.47.7141 (2014).
17. Yang, J. J. et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 1383–1392, doi:10.1158/1078-0432.CCR-13-0699 (2014).
18. Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Journal of medicinal chemistry 54, 6342–6363, doi:10.1021/jm2007613 (2011).
19. Curran, M. P. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72, 99–107, doi:10.2165/11207680-000000000-00000 (2012).
20. Xiao, D. et al. Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer. Oncotarget, doi:10.18632/oncotarget.10011 (2016).
21. Proietti, A. et al. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. Cancer cytopathology 122, 445–453, doi:10.1002/cncy.21418 (2014).
22. Debelle, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 1472–1482, doi:10.1158/1078-0432.CCR-11-2906 (2012).
23. Cai, W. et al. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 33, 3707–3709, doi:10.1200/JCO.2014.58.8293 (2015).
24. Abe, H. et al. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10, 800–805, doi:10.1097/JTO.0000000000000507 (2015).
25. Camidge, D. R. et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non-small cell lung cancer. Cancer 118, 4846–4849, doi:10.1002/cncr.27411 (2012).
26. Marchetti, A. et al. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 11, 487–495, doi:10.1016/j.jto.2015.12.111 (2016).
27. Wynes, M. W. et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **9**, 631–638, doi:10.1097/JTO.0000000000000115 (2014).

28. Minca, E. C. et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. *The Journal of molecular diagnostics: JMD* **15**, 341–346, doi:10.1016/j.jmoldx.2013.01.004 (2013).

29. Mino-Kenudson, M. et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clinical cancer research: an official journal of the American Association for Cancer Research* **16**, 1561–1571, doi:10.1158/1078-0432.CCR-09-2845 (2010).

30. van der Wekken, A. et al. Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional non-ALK-FISH in advanced non-small cell lung cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*, doi:10.1158/1078-0432.CCR-16-1631 (2017).

31. Shan, L. et al. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **10**, e37–39, doi:10.1097/JTO.0000000000000467 (2015).

32. Devarakonda, S., Morgensztern, D. & Govindan, R. Genomic alterations in lung adenocarcinoma. *The Lancet. Oncology* **16**, e342–351, doi:10.1016/S1470-2045(15)00077-7 (2015).

33. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. *Science* **346**, 256–259, doi:10.1126/science.1256930 (2014).

34. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. *Science* **346**, 251–256, doi:10.1126/science.1253462 (2014).

35. Xue, R. et al. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. *Gastroenterology* **150**, 998–1008, doi:10.1053/j.gastro.2015.12.033 (2016).

36. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. *Nature* **469**, 356–361, doi:10.1038/nature09650 (2011).

37. Tsao, M. S. et al. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* **33**, 3439–3446, doi:10.1200/JCO.2014.58.8335 (2015).

38. Travis, W. D. et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **6**, 244–285, doi:10.1097/JTO.0b013e318206a221 (2011).

39. Wittekind, C. TNM system: on the 7th edition of TNM classification of malignant tumors. *Der Pathologe* **31**, 331–332, doi:10.1007/s00292-010-1349-3 (2010).

40. Ibrahim, M. et al. ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer* **11**, 2241–2247, doi:10.1016/j.jto.2016.07.012 (2016).

41. Shan, L. et al. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma. *PloS one* **10**, e0130447, doi:10.1371/journal.pone.0130447 (2015).

**Acknowledgements**

This work was supported in part by grants from the National Natural Science Foundation of China (81650024), Beijing Hope Run Special Fund of Cancer Foundation of China (LC2015A06) and the Youth Backbone Program (to Jianming Ying) of Cancer Hospital, CAMS, Beijing, China.

**Author Contributions**

W.M. wrote the main manuscript text; N.L. and J.Y. did study conception and design; W.M., L.G., L.S. and X.L. did the experiments; W.M. and L.S. did data collection and participated in data analysis; All authors reviewed the manuscript.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017